APA (7th ed.) Citation

Berclaz, L. M., Altendorf-Hofmann, A., Lindner, L. H., Burkhard-Meier, A., Di Gioia, D., Dürr, H. R., . . . Knösel, T. (2023). TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS). Cancers, 15(10), 2735. https://doi.org/10.3390/cancers15102735

Chicago Style (17th ed.) Citation

Berclaz, Luc M., et al. "TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)." Cancers 15, no. 10 (2023): 2735. https://doi.org/10.3390/cancers15102735.

MLA (9th ed.) Citation

Berclaz, Luc M., et al. "TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)." Cancers, vol. 15, no. 10, 2023, p. 2735, https://doi.org/10.3390/cancers15102735.